Mitchel Berger

Direktor/Vorstandsmitglied bei POLARYX THERAPEUTICS, INC.

Commercial Services

Consumer Services

Profil

Mitchel Berger is currently the Director at the American Association of Neurological Surgeons.
Dr. Berger is also an Independent Director at Polaryx Therapeutics, Inc., starting in 2026.
Dr. Berger completed undergraduate education at Harvard College and graduate education at The University of Miami Leonard M.
Miller School of Medicine.

Aktive Positionen von Mitchel Berger

Unternehmen	Position	Beginn
POLARYX THERAPEUTICS, INC.	Direktor/Vorstandsmitglied	29.01.2026
American Association of Neurological Surgeons American Association of Neurological Surgeons Miscellaneous Commercial ServicesCommercial Services Operates association of neurological surgeons	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Mitchel Berger

Ausbildung von Mitchel Berger

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Mitchel Berger im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	4
American Association of Neurological Surgeons American Association of Neurological Surgeons Miscellaneous Commercial ServicesCommercial Services Operates association of neurological surgeons	Commercial Services
Harvard College Harvard College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The University of Miami Leonard M. Miller School of Medicine The University of Miami Leonard M. Miller School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Polaryx Therapeutics, Inc. Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders	Commercial Services